Sun Pharma Acquires Organon, Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion for CAR-T Therapy KLN-1010
Mega-Deals in Women's Health and Generics
Sun Pharmaceutical Industries has recorded the largest deal of the year by acquiring Organon for $11.75 billion. Sun Pharma aims to strengthen its global dominance by absorbing Organon's portfolio of over 70 women's health and generic medicines. This move proactively secures a massive supply chain and product line in anticipation of increased demand for pharmaceuticals due to the aging population in emerging markets. Through this acquisition, Sun Pharma will become a major player in the global bio-pharmaceutical market with annual sales of $12.4 billion.
In Vivo CAR-T and Next-Generation ADC Race
Eli Lilly acquired Kelonia Therapeutics for $7 billion, securing the in vivo CAR-T therapy candidate KLN-1010, which directly manipulates T cells within the body. This aims to overcome the limitations of existing ex vivo methods, such as complex and expensive external manufacturing processes and time delays, thereby expanding treatment options for patients with multiple myeloma. Gilead Sciences also acquired Tubulis for $5 billion, securing next-generation antibody-drug conjugate (ADC) technology and the TUB-040 pipeline, which is in Phase 1/2 clinical trials for ovarian cancer. These investments demonstrate the commitment of major pharmaceutical companies to reduce toxicity and increase target efficiency.
Strategic Moves in Rare Diseases and Central Nervous System
Neurocrine Biosciences acquired Soleno Therapeutics for $2.9 billion, gaining access to Vykat XR, the first FDA-approved drug for treating hyperphagia in patients with Prader-Willi Syndrome. Chiesi acquired KalVista Pharmaceuticals for $1.9 billion, acquiring commercialization rights for Sebetralstat, a small molecule drug for the treatment of hereditary angioedema (HAE). Teva also acquired Emalex Biosciences for $900 million, gaining access to Ecopipam, a treatment for Tourette Syndrome. The market for rare and difficult-to-treat diseases, which has high unmet needs, allows for exclusive pricing, making it a key driver of value creation.
Accelerated Global Licensing Agreements and AI Platform Utilization
Major pharmaceutical companies are diversifying risks through joint development and licensing agreements. AbbVie entered into a $745 million global licensing agreement with Haisco Pharmaceutical for a pain treatment, strengthening its early-stage pipeline. Roche initiated a joint development of a targeted protein degradation-antibody conjugate (DAC) with C4 Therapeutics, with a value exceeding $1 billion, and Eli Lilly established a partnership with Profluent, utilizing its artificial intelligence (AI) protein design platform, with a potential value of up to $2.25 billion. The convergence of innovative AI technologies and platforms is dramatically shortening the candidate discovery period.
This deal demonstrates the rebound in biotech valuations in 2026 and will serve as a catalyst for large-scale M&A, driving market liquidity recovery. In the short term, the Phase 1 clinical trial of Eli Lilly's KLN-1010 and the Phase 1/2 clinical trial of Gilead's TUB-040 will rapidly validate the commercial viability of next-generation platforms such as in vivo CAR-T and ADC. In the medium to long term, the $11.75 billion acquisition of Organon by Sun Pharma is expected to intensify the competition for market share in emerging markets for women's health and generics among multinational pharmaceutical companies, increasing pressure for portfolio diversification. In particular, the acquisition of Vykat XR, a treatment for Prader-Willi Syndrome, by Neurocrine and other companies in the rare disease space highlights the importance of market share acquisition through mergers and acquisitions by securing exclusive rights and raising barriers to entry for competitors.
Source: Labiotech (rss)
https://www.labiotech.eu/trends-news/top-biotech-deals-in-april-2026/